Effective oral cancer screening begins with your dentist

With oral cancer incidence rising, effective screening is more important than ever. That is why thousands of professionals have made ViziLite Plus with TBlue630 a part of their new oral cancer screening standard of care.

ViziLite's advanced light technology improves lesion visualization and makes it easier to identify occult lesions.

TBlue630, a pharmaceutical grade blue dye, allows you to mark lesions identified by ViziLite and helps to document their extent.

ViziLite Plus helps you to see abnormalities that include pre-cancerous and cancerous lesions, which means treatment for your patients may be simpler and less invasive. When detected early, oral cancer is 82%* curable and patients can live a healthy life. You can rely on us to spot early warning signs.